Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension.
来源：PubMed发布日期：2026-05-13作者：Navarro-Compán V, Kiltz U, Mease PJ, Dubreuil M, Gaffney K0 次点击